Covered recipient · General Payments record
KAREN PERKINS
General Payments · PY2018–2024
$1,960.63
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $352.53 | 15 |
| Education | $74.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $249.11 | 8 |
| Sage Therapeutics, Inc. | $71.62 | 2 |
| Exeltis, USA Inc. | $54.92 | 3 |
| ABBVIE INC. | $40.12 | 2 |
| Organon LLC | $11.75 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.67 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105240890 | CMS |
| ABBVIE INC. | $21.45 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105240894 | CMS |
| Astellas Pharma US Inc | $28.03 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139277994 | CMS |
| Astellas Pharma US Inc | $33.95 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139278586 | CMS |
| Astellas Pharma US Inc | $19.05 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139278738 | CMS |
| Astellas Pharma US Inc | $74.99 | 03/07/2024 | Education | Undisputed | 01/23/2026 | 1139279148 | CMS |
| Astellas Pharma US Inc | $32.06 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139278992 | CMS |
| Astellas Pharma US Inc | $11.20 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139279306 | CMS |
| Astellas Pharma US Inc | $32.37 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139277558 | CMS |
| Astellas Pharma US Inc | $17.46 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139279310 | CMS |
| Exeltis, USA Inc. | $16.84 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150001922 | CMS |
| Exeltis, USA Inc. | $16.84 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150001924 | CMS |
| Exeltis, USA Inc. | $21.24 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150001926 | CMS |
| Organon Llc | $11.75 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136211205 | CMS |
| Sage Therapeutics, Inc. | $32.37 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120409215 | CMS |
| Sage Therapeutics, Inc. | $39.25 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120406555 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.